Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
2.
J Eur Acad Dermatol Venereol ; 37(5): 954-964, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-36744752

RESUMEN

The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.


Asunto(s)
Acné Vulgar , Dermatología , Hidradenitis Supurativa , Rosácea , Venereología , Humanos , Hidradenitis Supurativa/terapia , Calidad de Vida , Rosácea/terapia
3.
J Dent Res ; 101(7): 859-869, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35148649

RESUMEN

Craniofacial and jaw bones have unique physiological specificities when compared to axial and appendicular bones. However, the molecular profile of the jaw osteoblast (OB) remains incomplete. The present study aimed to decipher the bone site-specific profiles of transcription factors (TFs) expressed in OBs in vivo. Using RNA sequencing analysis, we mapped the transcriptome of confirmed OBs from 2 different skeletal sites: mandible (Md) and tibia (Tb). The OB transcriptome contains 709 TF genes: 608 are similarly expressed in Md-OB and Tb-OB, referred to as "OB-core"; 54 TF genes are upregulated in Md-OB, referred to as "Md-set"; and 18 TF genes are upregulated in Tb-OB, referred to as "Tb-set." Notably, the expression of 29 additional TF genes depends on their RNA transcript variants. TF genes with no previously known role in OBs and bone were identified. Bioinformatics analysis combined with review of genetic disease databases and a comprehensive literature search showed a significant contribution of anatomical origin to the OB signatures. Md-set and Tb-set are enriched with site-specific TF genes associated with development and morphogenesis (neural crest vs. mesoderm), and this developmental imprint persists during growth and homeostasis. Jaw and tibia site-specific OB signatures are associated with craniofacial and appendicular skeletal disorders as well as neurocristopathies, dental disorders, and digit malformations. The present study demonstrates the feasibility of a new method to isolate pure OB populations and map their gene expression signature in the context of OB physiological environment, avoiding in vitro culture and its associated biases. Our results provide insights into the site-specific developmental pathways governing OBs and identify new major OB regulators of bone physiology. We also established the importance of the OB transcriptome as a prognostic tool for human rare bone diseases to explore the hidden pathophysiology of craniofacial malformations, among the most prevalent congenital defects in humans.


Asunto(s)
Regulación de la Expresión Génica , Osteoblastos , Humanos , Mandíbula , Cresta Neural , Osteoblastos/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/metabolismo
4.
Ann Chir Plast Esthet ; 64(1): 68-77, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29452717

RESUMEN

BACKGROUND: Hidradenitis suppurativa is a very debilitating disease, treated by antibiotics and excision. The reconstruction is usually done by secondary wound healing and/or split-thichness skin graft. The aim of this study was to evaluate the reconstruction of the axilla with local perforator flaps as a single stage surgical treatment. METHODS: This was a monocentric retrospective study conducted between November 2013 and June 2015. We included the patients with a severe axillary localization of the disease. Between 6 months and 1 year postoperatively, we noted length of complete healing, complications, patients satisfaction score about the surgery, DASH functional score, maximum abduction angle of the arm, and recurrence of the disease. RESULTS: Thirteen patients were included, for a total of seventeen affected axillae. We performed seven thoracodorsal artery perforator flaps, seven lateral intercostal artery perforator flaps and three serratus anterior artery perforator flaps. The mean duration of follow-up was 279.1±84.1 days (180-365). The average complete healing time was 20.5±13.5 days (10-60). Six axillae were compounded (35%). The average recurrence rate of HS was 0%. The average score in the DASH questionnaire was 68.6±35.3 points (39-152) and the average maximum abduction angle of the arm was 160.6±18.5 degrees. The average score on the satisfaction questionnaire was 36.5±5.6 points (25-43). CONCLUSION: This is a single stage, reliable and effective surgical procedure. The results are very encouraging, with a good quality of life, a low functional disability and a shorter healing time.


Asunto(s)
Axila/cirugía , Hidradenitis Supurativa/cirugía , Colgajo Perforante , Calidad de Vida , Rango del Movimiento Articular/fisiología , Articulación del Hombro/fisiología , Adolescente , Adulto , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Estudios Retrospectivos , Adulto Joven
5.
Ann Dermatol Venereol ; 145(5): 331-338, 2018 May.
Artículo en Francés | MEDLINE | ID: mdl-29704958

RESUMEN

OBJECTIVE: To provide physicians with an understanding of the factors behind significant delays in the diagnosis of hidradenitis suppurativa (HS) in France. PATIENTS AND METHODS: This prospective multicentre national study conducted from October 2015 to March 2016 included all patients consulting for HS. Patient data were collected by means of a standardized questionnaire. Univariate and multivariate analyses were conducted to collect factors associated with a significant time to diagnosis of at least 5.5years, defined as the period between the onset of initial clinical signs and the time of formal diagnosis. RESULTS: The 16 participating centres enrolled 312 patients (62% women), of average age 35years. The average age at onset of HS was 22years. Before formal diagnosis by a dermatologist (64% of cases), 170 (54%), 114 (37%) and 45 (15%) patients had previously consulted at least 3, 5 and 10 general physicians, respectively. The average time between the initial clinical signs of HS, the first dermatology visit and the definitive diagnosis was 6.2 and 8.4 years, respectively. Active smoking (OR adjusted 1.85; P=0.027) and disease onset at a younger age (adjusted OR 0.92; P<0.001) were both associated with significant delays in diagnosis. CONCLUSION: These results emphasized misdiagnosis among HS patients but did not evidence any association between either sociodemographic or economic characteristics and the existence of significant times to diagnosis.


Asunto(s)
Diagnóstico Tardío , Errores Diagnósticos , Hidradenitis Supurativa/diagnóstico , Adulto , Edad de Inicio , Estudios Transversales , Femenino , Francia/epidemiología , Humanos , Masculino , Estudios Prospectivos , Fumar/epidemiología
8.
Clin Radiol ; 69(10): 1027-33, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24957855

RESUMEN

AIM: To investigate the feasibility of gadoxetate disodium-enhanced magnetic resonance (MR) cholangiography in chronic obstructive cholestatic biliary disease in the clinical setting. MATERIALS AND METHODS: Twenty-three patients with dilated bile duct trees and ten volunteers underwent gadoxetate disodium-enhanced liver MR cholangiography and were enrolled in the present retrospective study. Gadoxetate disodium was given in a standardized manner as a bolus injection at a dose of 0.25 mmol/kg of body weight (0.1 ml/kg). Region of interest-based measurement of mean enhancement of the dilated bile ducts was performed in series before gadoxetate disodium administration and during hepatobiliary phases. RESULTS: Direct comparison of mean bile duct enhancement during hepatobiliary phases in the clinical imaging window between healthy volunteers [4.7 ± 2.2 arbitrary units (au)] and patients with dilated bile ducts (0.1 ± 0.3 au) revealed significantly lower or absent enhancement in dilated bile ducts (p = 0.001). CONCLUSION: Standard clinical gadoxetate disodium-enhanced MR cholangiography is not a reliable technique for the evaluation of the biliary trees, because of altered biliary gadoxetate disodium elimination in patients with chronic obstructive biliary diseases.


Asunto(s)
Enfermedades de los Conductos Biliares/diagnóstico , Colangiografía/métodos , Medios de Contraste , Gadolinio DTPA , Aumento de la Imagen/métodos , Imagen por Resonancia Magnética/métodos , Adulto , Conductos Biliares/patología , Colestasis/diagnóstico , Enfermedad Crónica , Estudios de Factibilidad , Femenino , Humanos , Masculino , Estudios Retrospectivos
10.
Clin Pharmacol Ther ; 92(1): 103-11, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22588604

RESUMEN

Nuclear receptors such as the constitutive androstane receptor (CAR) are central factors that link drug exposure to the activities of drug metabolism and elimination. In order to determine the in vivo effects of efavirenz, a CAR activator, the expression of target genes was determined in duodenal biopsies obtained from 12 healthy volunteers before treatment and after 10 days of treatment with efavirenz; concomitant administration of the cholesterol inhibitor ezetimibe produced no significant difference. However, in in vitro studies, efavirenz significantly increased CYP2B6 expression in several cell types, suggesting that the drug transactivates CAR. This hypothesis is supported by our findings that there is significant induction of CAR target genes in in vivo peripheral blood mononuclear cells (PBMCs) isolated from healthy volunteers treated with multiple doses of efavirenz. The impact of efavirenz on hepatic metabolism in vivo was confirmed by significant changes in plasma 4ß-hydroxycholesterol and bilirubin levels and the area under the curve (AUC) of efavirenz. Induction of CYP2B6 mRNA expression correlated with the decrease in the AUC of efavirenz (r = 0.61; P = 0.036). Taken together, our results provide evidence that efavirenz exerts compartment-specific inductive capacity in vivo.


Asunto(s)
Benzoxazinas/farmacocinética , Regulación de la Expresión Génica/efectos de los fármacos , Inactivación Metabólica/genética , Receptores Citoplasmáticos y Nucleares/genética , Adulto , Alquinos , Anticolesterolemiantes/farmacocinética , Área Bajo la Curva , Hidrocarburo de Aril Hidroxilasas/genética , Azetidinas/farmacocinética , Biopsia , Receptor de Androstano Constitutivo , Ciclopropanos , Citocromo P-450 CYP2B6 , Interacciones Farmacológicas , Monitoreo de Drogas/métodos , Duodeno/metabolismo , Duodeno/patología , Ezetimiba , Humanos , Leucocitos Mononucleares/metabolismo , Hígado/metabolismo , Masculino , Oxidorreductasas N-Desmetilantes/genética , Inhibidores de la Transcriptasa Inversa/farmacocinética
11.
Clin Pharmacol Ther ; 91(3): 506-13, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22297387

RESUMEN

Hypercholesterolemia frequently occurs in patients treated with efavirenz who cannot be treated adequately with statins because of drug interactions. These patients may benefit from cholesterol-lowering therapy with ezetimibe. This study determined the influence of single-dose and multiple-dose efavirenz (400 mg/day for 9 days) on the pharmacokinetics and sterol-lowering of ezetimibe (10 mg) in 12 healthy subjects. In addition, the influence of efavirenz on genome-wide intestinal expression and in vitro function of ABCB1, ABCC2, UGT1A1, and OATP1B1 was studied. Efavirenz (multiple dose) had no influence on the pharmacokinetics and lipid-lowering functions of ezetimibe. Intestinal expression of enzymes and transporters (e.g., ABCB1, ABCC2, and UGT1A1) was not affected by chronic efavirenz. Efavirenz (single dose) slightly increased ezetimibe absorption and markedly decreased exposure to ezetimibe-glucuronide (single dose and multiple dose), which may be explained by inhibition of UGT1A1 and ABCB1 (in vitro data). Ezetimibe had no effect on the disposition of efavirenz. Consequently, ezetimibe may be a safe and efficient therapeutic option in patients with HIV infection.


Asunto(s)
Anticolesterolemiantes/farmacocinética , Azetidinas/farmacocinética , Benzoxazinas/farmacología , Mucosa Intestinal/metabolismo , Intestinos/efectos de los fármacos , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Adulto , Alquinos , Animales , Anticolesterolemiantes/farmacología , Azetidinas/farmacología , Benzoxazinas/farmacocinética , Transporte Biológico/efectos de los fármacos , Línea Celular , Línea Celular Transformada , Ciclopropanos , Citocromo P-450 CYP3A/metabolismo , Perros , Interacciones Farmacológicas , Ezetimiba , Expresión Génica/efectos de los fármacos , Glucuronosiltransferasa/antagonistas & inhibidores , Glucuronosiltransferasa/genética , Glucuronosiltransferasa/metabolismo , Células HEK293 , Infecciones por VIH/tratamiento farmacológico , Humanos , Hipercolesterolemia/tratamiento farmacológico , Absorción Intestinal/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/metabolismo , Transportador 1 de Anión Orgánico Específico del Hígado , Masculino , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/genética , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Transportadores de Anión Orgánico/genética , Transportadores de Anión Orgánico/metabolismo , ARN Mensajero/genética , Adulto Joven
12.
Clin Pharmacol Ther ; 89(4): 524-8, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21368751

RESUMEN

Immunosuppressive therapy is frequently associated with hypercholesterolemia, calling for lipid-lowering treatment without adverse drug interactions. One option is treatment with the cholesterol absorption inhibitor ezetimibe. We have shown in vitro that ezetimibe and tacrolimus may interact in competition for intestinal UGT1A1 and ABCB1 at concentrations reached in gut lumen after oral administration. However, this clinical study in healthy volunteers showed that the expected pharmacokinetic interaction between ezetimibe and tacrolimus is not of clinical relevance.


Asunto(s)
Anticolesterolemiantes/farmacocinética , Azetidinas/farmacocinética , Inmunosupresores/farmacocinética , Tacrolimus/farmacocinética , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Administración Oral , Adulto , Animales , Anticolesterolemiantes/farmacología , Azetidinas/farmacología , Línea Celular , Estudios Cruzados , Perros , Interacciones Farmacológicas , Ezetimiba , Femenino , Glucuronosiltransferasa/metabolismo , Humanos , Inmunosupresores/farmacología , Técnicas In Vitro , Masculino , Tacrolimus/farmacología , Adulto Joven
13.
Clin Pharmacol Ther ; 87(6): 663-7, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20220747

RESUMEN

Organ transplant recipients who have dyslipidemia related to immunosuppression may benefit from cholesterol-lowering therapy with ezetimibe, a substrate of ABCB1, ABCC2, and OATP1B1. Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2. However, competition between sirolimus and ezetimibe for ABCB1 and OATP1B1 is not of major clinical relevance, as confirmed in our randomized, controlled, single-dose study in healthy subjects.


Asunto(s)
Anticolesterolemiantes/farmacocinética , Azetidinas/farmacocinética , Inmunosupresores/farmacocinética , Sirolimus/farmacocinética , Adulto , Animales , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/farmacología , Azetidinas/administración & dosificación , Azetidinas/farmacología , Línea Celular , Células Cultivadas , Estudios Cruzados , Perros , Relación Dosis-Respuesta a Droga , Ezetimiba , Femenino , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/farmacología , Masculino , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos , Transportadores de Anión Orgánico/metabolismo , Sirolimus/administración & dosificación , Sirolimus/farmacología , Transfección , Adulto Joven
14.
Eur Surg Res ; 42(4): 209-15, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19279385

RESUMEN

Colonic anastomosis healing in hypothyroidism was evaluated. Twenty Wistar rats were separated into two groups: the study group (n = 10), which underwent total thyroidectomy to induce hypothyroidism, and the control group (n = 10). After 10 weeks, hypothyroid status was confirmed by blood tests (p < 0.0001). Three days later, a colonic anastomosis was performed, and the animals were sacrificed 1 week later. The colon containing the anastomosis was resected for bursting strength tests and histological studies. The slides were stained with hematoxylin-eosin and with Sirius red to quantify and classify the collagen. Reduced values were found for the bursting strength test (p = 0.0006) and for collagen density in the experimental group. There was a prevalence of immature type III collagen (p < 0.0001) and a decrease in mature type I collagen (p < 0.0001) in the hypothyroid group.


Asunto(s)
Colon/cirugía , Hipotiroidismo/fisiopatología , Cicatrización de Heridas , Anastomosis Quirúrgica , Animales , Colon/patología , Masculino , Presión , Ratas , Ratas Wistar
15.
AJNR Am J Neuroradiol ; 27(10): 2149-54, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17110686

RESUMEN

BACKGROUND AND PURPOSE: We objectively assessed surface structural changes of the hippocampus in mesial temporal sclerosis (MTS) and assessed the ability of large-deformation high-dimensional mapping (HDM-LD) to demonstrate hippocampal surface symmetry and predict group classification of MTS in right and left MTS groups compared with control subjects. METHODS: Using eigenvector field analysis of HDM-LD segmentations of the hippocampus, we compared the symmetry of changes in the right and left MTS groups with a group of 15 matched controls. To assess the ability of HDM-LD to predict group classification, eigenvectors were selected by a logistic regression procedure when comparing the MTS group with control subjects. RESULTS: Multivariate analysis of variance on the coefficients from the first 9 eigenvectors accounted for 75% of the total variance between groups. The first 3 eigenvectors showed the largest differences between the control group and each of the MTS groups, but with eigenvector 2 showing the greatest difference in the MTS groups. Reconstruction of the hippocampal deformation vector fields due solely to eigenvector 2 shows symmetrical patterns in the right and left MTS groups. A "leave-one-out" (jackknife) procedure correctly predicted group classification in 14 of 15 (93.3%) left MTS subjects and all 15 right MTS subjects. CONCLUSION: Analysis of principal dimensions of hippocampal shape change suggests that MTS, after accounting for normal right-left asymmetries, affects the right and left hippocampal surface structure very symmetrically. Preliminary analysis using HDM-LD shows it can predict group classification of MTS and control hippocampi in this well-defined population of patients with MTS and mesial temporal lobe epilepsy (MTLE).


Asunto(s)
Epilepsia del Lóbulo Temporal/patología , Hipocampo/patología , Imagen por Resonancia Magnética , Lóbulo Temporal/patología , Adulto , Mapeo Encefálico , Femenino , Humanos , Imagen por Resonancia Magnética/métodos , Masculino , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Esclerosis
17.
Ann Dermatol Venereol ; 132(12 Pt 1): 962-5, 2005 Dec.
Artículo en Francés | MEDLINE | ID: mdl-16446637

RESUMEN

AIM: To determine the clinical features of contact dermatitis caused by antiseptics and to ascertain whether the substance responsible is the antiseptic itself or the excipients. PATIENTS AND METHODS: A multicenter, retrospective study based on analysis of all cases reported over a 2-year period to the Dermato-Allergology Vigilance network known as Revidal. Each dossier contained details of the clinical characteristics of lesions, the incriminated antiseptic, the mode of exposure and the results of patch tests done with the antiseptic in question. RESULTS: 75 patients (mean age: 44 years) were sensitized to chlorhexidine (14 cases), hexamidine (20 cases), povidone iodine (14 cases), mercuric antiseptics (3 cases), triclocarban (Septivon, 17 cases), hexamidine-chlorhexidine-chlorocresol (Cytéal, 4 cases), or chlorhexidine surfactant (Hibiscrub), cetrimide or chlorhexidine digluconate (Diaseptyl) (1 case each). Exposure was therapy-related (68 cases), work-related (6 cases; 5 in health workers and 1 in a cattle farmer due to povidone-iodine) or related to cosmetics (1 case, hexamidine). The clinical features consisted mainly of localized contact dermatitis, although generalized eczema occurred in 9 cases due to hexamidine contact. Sensitization was due to the antiseptic itself (53 cases) or to the excipients alone (22 cases), particularly in the 17 cases caused by Septivon. In 27/75 cases (35%), patients exhibited polysensitization to antiseptics belonging to different chemical classes or to other topical drugs. CONCLUSION: Sensitization to antiseptics is probably not rare, with various sources of exposure being present in everyday life. Patch tests are essential for diagnosis in order to distinguish between antiseptic-related and excipient-related sensitization and to screen for polysensitization to topical drugs.


Asunto(s)
Antiinfecciosos Locales/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Administración Tópica , Adolescente , Adulto , Sistemas de Registro de Reacción Adversa a Medicamentos , Anciano , Anciano de 80 o más Años , Antiinfecciosos Locales/inmunología , Antiinfecciosos Locales/uso terapéutico , Niño , Preescolar , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/epidemiología , Excipientes/efectos adversos , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Exposición Profesional , Pruebas del Parche , Estudios Retrospectivos
18.
Brain ; 127(Pt 8): 1731-40, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15231583

RESUMEN

MRI-based evaluation of the hippocampus is important in the assessment and treatment of patients with mesial temporal lobe epilepsy (MTLE). Using MRI-based large-deformation high-dimensional mapping (HDM-LD), which allows structural evaluation of regions of the hippocampus, we document the HDM-LD-defined pattern of hippocampal deformation in MTLE patients compared with matched controls. In 30 subjects with MTLE and confirmed medial temporal lobe sclerosis (MTS), we performed measurements of intracranial area, brain parenchymal volume and deformation-based hippocampal segmentations, and then grouped patients into right and left MTS groups (resulting in 15 subjects in each group). Using HDM-LD techniques, we compared the right and left MTS groups with a group of 15 matched controls. Analysis included both the MTS and contralateral hippocampi, and covariance for changes in brain parenchymal volume. Final results were interpreted using a segmentation showing normal hippocampal surface subfield anatomy. Comparing the MTS groups with controls, after covarying with brain parenchymal volume, the MTS hippocampi showed significant volume loss (P < 0.0001), contralateral hippocampi showed no significant volume loss. HDM-LD techniques showed significant shape changes, with marked inward deviation in the Sommer sector of the MTS hippocampi. In the contralateral hippocampi, the inferior surface of the hippocampal body showed inward deformation in the medial aspect of the subiculum, with minimal involvement of the Sommer sector. HDM-LD shows involvement of subregions of the hippocampus which are consistent with MTS histopathology. Contralateral hippocampi show different HDM-LD changes, suggesting that the underlying disease process in the contralateral hippocampi is different from MTS.


Asunto(s)
Epilepsia del Lóbulo Temporal/patología , Hipocampo/patología , Adulto , Encéfalo/patología , Mapeo Encefálico/métodos , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Esclerosis , Lóbulo Temporal/patología
20.
Magn Reson Imaging ; 19(1): 129-32, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11295355

RESUMEN

A 55 year old female receiving gemcitabine for stage IV non-small cell carcinoma of the lung developed the clinical-radiologic syndrome of posterior reversible encephalopathy syndrome (PRES). She had clinical manifestations of headaches, increasing somnolence and tonic-clonic seizures. The fluid-attentuated inversion recovery (FLAIR) MR imaging sequence conspicuously showed bihemispheric, symmetrical cortical and subcortical white matter hyperintensities that preponderantly involved the parietal and occipital lobes. Diffusion-weighted imaging (DWI) sequence reflected the preponderant existence of vasogenic edema in the involved areas. MR spectroscopy showed no significant N-acetyl aspartate (NAA) depletion or lactate elevation prospectively, indicating the absence of significant neuronal loss and reversibility of the brain parenchymal changes. The clinical and radiologic manifestations essentially resolved completely with discontinuation of the drug.


Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Antimetabolitos Antineoplásicos/uso terapéutico , Lesiones Encefálicas/inducido químicamente , Lesiones Encefálicas/patología , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Desoxicitidina/efectos adversos , Desoxicitidina/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Encéfalo/patología , Desoxicitidina/análogos & derivados , Femenino , Humanos , Persona de Mediana Edad , Síndrome , Gemcitabina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...